Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.42 USD
−69.33 M USD
0.00 USD
19.50 M
About ArriVent BioPharma, Inc.
Sector
CEO
Zheng Bin Yao
Headquarters
Newtown Square
Website
Founded
2021
FIGI
BBG011N37VQ0
Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company. It focuses on identifying, licensing and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company was founded Zheng Bin Yao and Stuart Lutzker on April 14, 2021 and is headquartered in Newtown Square, PA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of AVBP is 27.26 USD — it has decreased by −1.47% in the past 24 hours. Watch ArriVent BioPharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange ArriVent BioPharma, Inc. stocks are traded under the ticker AVBP.
AVBP stock has risen by 3.59% compared to the previous week, the month change is a −8.33% fall, over the last year ArriVent BioPharma, Inc. has showed a 13.58% increase.
We've gathered analysts' opinions on ArriVent BioPharma, Inc. future price: according to them, AVBP price has a max estimate of 41.00 USD and a min estimate of 36.00 USD. Watch AVBP chart and read a more detailed ArriVent BioPharma, Inc. stock forecast: see what analysts think of ArriVent BioPharma, Inc. and suggest that you do with its stocks.
AVBP reached its all-time high on Nov 8, 2024 with the price of 36.37 USD, and its all-time low was 14.35 USD and was reached on Apr 25, 2024. View more price dynamics on AVBP chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
AVBP stock is 3.58% volatile and has beta coefficient of 0.64. Track ArriVent BioPharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is ArriVent BioPharma, Inc. there?
Today ArriVent BioPharma, Inc. has the market capitalization of 918.59 M, it has increased by 3.38% over the last week.
Yes, you can track ArriVent BioPharma, Inc. financials in yearly and quarterly reports right on TradingView.
ArriVent BioPharma, Inc. is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
AVBP earnings for the last quarter are −0.61 USD per share, whereas the estimation was −1.00 USD resulting in a 39.16% surprise. The estimated earnings for the next quarter are −0.78 USD per share. See more details about ArriVent BioPharma, Inc. earnings.
ArriVent BioPharma, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
AVBP net income for the last quarter is −20.56 M USD, while the quarter before that showed −21.87 M USD of net income which accounts for 5.99% change. Track more ArriVent BioPharma, Inc. financial stats to get the full picture.
No, AVBP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 40.00 employees. See our rating of the largest employees — is ArriVent BioPharma, Inc. on this list?
Like other stocks, AVBP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ArriVent BioPharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ArriVent BioPharma, Inc. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ArriVent BioPharma, Inc. stock shows the sell signal. See more of ArriVent BioPharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.